Provincial Drug Coverage Chart
As of February 2011
Access to a generic equivalent is generally reported to be identical to that of the relevant brand name medication.
|
TYPE OF LISTING |
|||||||||
|
Province |
Bisphosphonates |
Calcitonin |
SERMs |
Teriparatide (PTH) |
|||||
|
Etidronate |
Alendronate |
Risedronate |
Zoledronic acid |
||||||
|
Didrocal® Generics available |
Fosamax® Generics available |
Fosavance® |
Actonel® Generics available |
Actonel Plus Calcium® |
Aclasta® |
Miacalcin® Generics available |
Raloxifene Evista® |
FORTEO® |
|
|
BC |
Open Access |
Restricted Access |
Restricted Access |
Restricted Access |
Not Accessible |
Not Accessible |
Not Accessible |
Restricted Access |
Not Accessible |
|
AB*** |
Open Access |
Restricted Access |
Restricted Access |
Restricted Access |
Not Accessible |
Restricted Access |
Restricted Access |
Restricted Access |
Not Accessible |
|
SK*** |
Open Access |
Restricted Access |
Restricted Access |
Restricted Access |
Not Accessible |
Not Accessible |
Restricted Access |
Restricted Access |
Not Accessible |
|
MB |
Open Access |
Restricted Access |
Not Accessible |
Restricted Access |
Not Accessible |
Not Accessible |
Restricted Access |
Restricted Access |
Not Accessible |
|
ON |
Open Access |
Open Access |
Open Access |
Open Access |
Not Accessible |
Restricted Access* |
Not Accessible |
Restricted Access |
Not Accessible |
|
QC*** |
Open Access |
Open Access |
Open Access |
Open Access |
Open Access |
Restricted Access** |
Open Access |
Open Access |
Restricted Access |
|
NB |
Open Access |
Restricted Access |
Not Accessible |
Restricted Access |
Not Accessible |
Not Accessible |
Restricted Access |
Restricted Access |
Not Accessible |
|
NS*** |
Open Access |
Restricted Access |
Not Accessible |
Restricted Access |
Not Accessible |
Not Accessible |
Restricted Access |
Restricted Access |
Not Accessible |
|
PEI |
Open Access |
Restricted Access |
Not Accessible |
Restricted Access |
Not Accessible |
Not Accessible |
Restricted Access |
Not Accessible |
Not Accessible |
|
NFLD |
Open Access |
Restricted Access |
Restricted Access |
Restricted Access |
Not Accessible |
Not Accessible |
Restricted Access |
Restricted Access |
Not Accessible |
|
YT |
Open Access |
Open Access |
Not Accessible |
Restricted Access |
Not Accessible |
Not Accessible |
Restricted Access |
Open Access |
Not Accessible |
*Aclasta® is approved for reimbursement under the Ontario Public Drug Programs “Exceptional Access Program” for the treatment of osteoporosis in males and PMO in women who are ambulatory and who are unable to take oral medications because they are on total parenteral nutrition (TPN) or are NPO (i.e. unable to take anything by mouth).
**Aclasta® (zoledronic acid 5mg/100mL) was approved in Canada for the treatment of postmenopausal osteoporosis (PMO) in October 2007. As of March 2009, Aclasta (TM) is also approved as a treatment to increase bone mineral density in men with osteoporosis and for the treatment and prevention of osteoporosis in men and women, caused by glucocorticoid medications such as prednisone, to increase bone mineral density. It is reimbursed in Quebec for the treatment of PMO among women who cannot tolerate oral bisphosphonates.
***As of February 2011, Quebec becomes the first province to list Prolia® (denosumab) on public and private drug plans. Prolia® is listed as a médicament d'exception for treatment of women with postmenopausal osteoporosis who cannot take an oral bisphosphonate due to intolerance or contraindication. As of July 2011, Alberta, Saskatchewan and Nova Scotia added Prolia® to their provincial drug plans under Restricted Access.